Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature
Health Science Reports · 2026-04 · 9 (4)
DOI: 10.1002/hsr2.72301 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Health Science Reports, online erschienen am 06.04.2026. Verfasst von Mahshid Sadat Ansari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Razi Hospital Tehran University of Medical Sciences Tehran Iran. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Palmoplantar pustulosis (PPP) is a chronic, recurrent, inflammatory disease and assumed to be a subtype of psoriasis. Pustular psoriasis (PP) is a chronic inflammatory disease that is further subclassified into various entities with different presentations including generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPPP). Given the central role of the JAK–STAT pathway in cytokine signaling, this systematic review evaluated the effectiveness and safety of Janus kinase inhibitors (JAK‐I) in these PP subtypes.
Methods
Following PRISMA 2020 guidelines, a systematic search was conducted across PubMed/Medline, Scopus, Web of Science, and Embase up to November 13, 2025. Eligible studies included assessing JAK‐I in PPP, GPP, or PPPP. Exclusion criteria were reviews, articles without full‐text, SAPHO syndrome, and animal/in vitro studies. Risk of bias was assessed using the NHLBI quality assessment tool for clinical studies and Murad et al.'s checklist for case reports/series.
Results
Thirty‐seven studies were included (29 case reports, 4 case series, and 4 clinical studies), encompassing 157 patients (60.5% female; mean age 46.8 years). Treatments involved tofacitinib, upadacitinib, baricitinib, abrocitinib, and topical ruxolitinib. In PPP, pooled meta‐analysis demonstrated a PPPASI‐50 response rate of 85.5% (95% CI, 71.3–93.3), with upadacitinib achieving 90.9% (95% CI, 81.7–95.7). Case reports and series showed 88.1% clearance or near‐clearance within a mean of 2.5 months. GPP patients ( n = 5) achieved rapid clearance or marked improvement within 2–12 weeks. Adverse events (18.7%) were generally mild, most commonly acneiform eruptions, headache, and transient liver enzyme elevations, with no severe events reported.
Conclusion
JAK‐I demonstrate high response rates and rapid improvement with manageable safety profiles. However, the current evidence is limited by small sample sizes, short follow‐up durations, and reliance on case‐based data. They represent a promising therapeutic option and warrant further evaluation in larger controlled studies to establish long‐term efficacy and safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Razi Hospital Tehran University of Medical Sciences Tehran Iran.
ORCID-Profile: Mahshid Sadat Ansari, Sama Heidari, Elnaz Pourgholi, Seyed Mohammad Vahabi
Zitieren
APA
Ansari, M. S., Heidari, S., Pourgholi, E., Bahramian, S., Tootoonchi, N., & Vahabi, S. M. (2026). Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature. Health Science Reports, 9(4). https://doi.org/10.1002/hsr2.72301
Vancouver
Ansari MS, Heidari S, Pourgholi E, Bahramian S, Tootoonchi N, Vahabi SM. Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature. Health Science Reports. 2026;9(4). doi:10.1002/hsr2.72301
BibTeX
@article{Ansari2026,
author = {Ansari, Mahshid Sadat and Heidari, Sama and Pourgholi, Elnaz and Bahramian, Saeed and Tootoonchi, Nasim and Vahabi, Seyed Mohammad},
title = {Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature},
journal = {Health Science Reports},
year = {2026},
volume = {9},
number = {4},
doi = {10.1002/hsr2.72301}
}
EUVIMED